

AMENDMENTS TO THE SPECIFICATION:

Please amend page 10, in the Figure 1 legend as follows:

Figure 1: Partial sequence of pGEX2ThCD83ext vector. The sequence of the extracellular CD83 domain is shown in bold letters. The amino-acid sequence "GSPG" (SEQ ID NO:14) was added to the N-terminus of the extracellular CD83 domain and is part of the thrombin cleavage site which is underlined. The C-terminal amino acid "I" is part of the cytoplasmic domain of CD83. SmaI and EcoRI cloning sites are indicated by a broken line (--) .

Please amend page 11, in the Figure 8 legend as follows:

Figure 8: Partial sequence of pGEX2ThCD83ext_mut129_CtoS vector. The sequence of the extracellular CD83 domain is shown in bold letters. The exchanged nucleotide and amino acid residues are enlarged. The amino-acid sequence "GSPG" (SEQ ID NO:14) was added to the N-terminus of the extracellular CD83 domain and is part of the thrombin cleavage site which is underlined. The C-terminal amino acid "I" is part of the cytoplasmic domain of CD83. SmaI and EcoRI cloning sites are indicated by a broken line (--) .

Please amend the paragraph bridging pages 12-13 of the specification as follows:

Hence according to embodiment (1) of the invention the soluble form of a member of the CD83 family of proteins, a fragment thereof, or a functional derivative thereof may be used for the production of a medicament for the treatment or prevention of a disease or medical condition caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. Preferably soluble CD83 protein comprises at least amino acid residues 20 to 144, or 20 to 145 of SEQ ID NO: 2. Suitable fragments are those having the same activity and conformation as natural CD83. Suitable derivatives include, but are not limited to, those proteins having additional sequences attached to its C- or N-terminus, e.g. those carrying part of a transmembrane domain at their C-terminus or carrying at their N-terminus a short functional peptide (Gly-Ser-Pro-Gly (SEQ ID NO:14)) may be used. The medicaments containing these proteins and fragments are useful for the treatment or prevention of paralysis, as for example seen with progressive multiple sclerosis.

Please amend the paragraph bridging pages 21-22 of the specification as follows:

Particular preferred additions are those where the soluble CD83 protein as defined hereinbefore has one or more amino acid residues derived from the neighbouring intracellular domain at its C-terminus, preferably the soluble CD83 protein comprises amino acid residues 20 to 145 of SEQ ID NO:2; and/or has functional sequences attached to its N-terminus, preferably functional sequences of up to 10 amino acid residues, and most preferably carries at the N-terminus the additional amino acids Gly-Ser-Pro-Gly (SEQ ID NO: 14).

In the Sequence Listing, please insert replacement sheet 10 after Sequence Listing page 9.